Showing results (71-80 of 159) with videos related to

Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2022
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid LeukemiaMarina Konopleva, Michael J Thirman, Keith W Pratz, et al.
Oncotarget|January 13, 2017
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitorsBao Nguyen, Allen B Williams, David J Young, et al.
Haematologica|December 24, 2013
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasmsJoshua F Zeidner, Judith E Karp, Amanda L Blackford, et al.
Blood|January 26, 2011
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivoTakashi Sato, Xiaochuan Yang, Steven Knapper, et al.
Leukemia & Lymphoma|September 28, 2011
Risk assessment in human immunodeficiency virus-associated acute myeloid leukemiaMichael W Evans, Anthony D Sung, Ivana Gojo, et al.
British Journal of Haematology|August 10, 2007
Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cellsKyu-Tae Kim, Kristin Baird, Sean Davis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2016
Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative NeoplasmsKeith W Pratz, Brian D Koh, Anand G Patel, et al.
British Journal of Haematology|March 16, 2007
FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cellsLi Li, Obdulio Piloto, Kyu-Tae Kim, et al.
Signal Transduction and Targeted Therapy|May 24, 2021
FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activationRuiqi Zhu, Li Li, Bao Nguyen, et al.
Blood|January 11, 2014
TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivoHayley Ma, Bao Nguyen, Li Li, et al.
Pageof 16